GD-DESVENLAFAXINE TABLET (EXTENDED-RELEASE)

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)

متاح من:

GENMED A DIVISION OF PFIZER CANADA ULC

ATC رمز:

N06AX23

INN (الاسم الدولي):

DESVENLAFAXINE

جرعة:

50MG

الشكل الصيدلاني:

TABLET (EXTENDED-RELEASE)

تركيب:

DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 50MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

7/14/28/30/90

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS

ملخص المنتج:

Active ingredient group (AIG) number: 0152509001; AHFS:

الوضع إذن:

CANCELLED PRE MARKET

تاريخ الترخيص:

2020-04-02

خصائص المنتج

PRODUCT MONOGRAPH
Pr
GD
*
-DESVENLAFAXINE
Desvenlafaxine Succinate
Extended Release Tablets 50 and 100 mg desvenlafaxine as
desvenlafaxine succinate
Antidepressant
GenMed, a Division of Pfizer Canada Inc.
17,300 Trans-Canada Highway
Kirkland, Quebec
H9J 2M5
Date of Preparation:
January 24, 2018
Submission Control No.: 212741
*
GD is a trademark of Pfizer Canada Inc.
GenMed, a division of Pfizer Canada Inc., Licensee
©
Pfizer Canada Inc. 2017
_GD-Desvenlafaxine (desvenlafaxine succinate) Product Monograph _
_Page 2 of 51 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................................3
SUMMARY PRODUCT INFORMATION
...........................................................................3
INDICATIONS AND CLINICAL USE
................................................................................3
CONTRAINDICATIONS
......................................................................................................4
WARNINGS AND PRECAUTIONS
....................................................................................4
ADVERSE REACTIONS
....................................................................................................12
DRUG INTERACTIONS
....................................................................................................22
DOSAGE AND ADMINISTRATION
................................................................................26
OVERDOSAGE
...................................................................................................................29
ACTION AND CLINICAL PHARMACOLOGY
...............................................................31
STORAGE AND STABILITY
............................................................................................35
SPECIAL HANDLING INSTRUCTIONS
..........................................................................35
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................35
PART II: SCIENTIFIC INFORMATION
.....................